AstraZeneca PLC vs Canon Inc.: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and Canon Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating Canon Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and Canon Inc. is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against ~$31B for Canon Inc., while their respective market capitalizations stand at $254.6B and $25.6B. AstraZeneca PLC is headquartered in United Kingdom and Canon Inc. in Japan, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

Canon Inc.: Canon is a diversified Japanese manufacturer organized into four business units. Printing (office multifunction devices, laser and inkjet printers, production presses) is the largest. Imaging includes EOS cameras, RF lenses, cinema cameras and Axis network cameras. Medical, built on the 2016 purchase of Toshiba Medical Systems, makes CT, MRI, ultrasound and X-ray equipment. Industrial supplies semiconductor and flat-panel lithography tools and Canon Tokki OLED deposition systems. The group had 321 consolidated subsidiaries and 165,547 employees at the end of 2025, and its shares trade on the Tokyo Stock Exchange under code 7751.

AstraZeneca PLC and Canon Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and Canon Inc..

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

Canon Inc. business model: Canon designs, builds and sells hardware, then earns recurring revenue from consumables, service contracts and software on the installed base. In 2025 the Printing Business Unit produced ~$16.7 billion (¥2,494.4 billion) of sales (54%), split between office multifunction devices (~$7.13 billion (¥1,063.7 billion)), prosumer laser and inkjet printers (~$6.66 billion (¥993.4 billion)) and production presses (~$2.93 billion (¥437.3 billion)); toner, ink and maintenance on machines already in the field account for much of that income. Imaging (~$7.07 billion (¥1,054.9 billion), 23%) covers EOS cameras and lenses (~$4.19 billion (¥625.5 billion)) plus network cameras and video software from Axis and Milestone (~$2.88 billion (¥429.4 billion)). Medical (~$3.89 billion (¥580.6 billion), 13%) sells CT, MRI, ultrasound and X-ray systems and service. Industrial (~$2.42 billion (¥361.1 billion), 8%) sells semiconductor and flat-panel lithography tools, Canon Tokki OLED deposition systems and sputtering equipment. Canon sells through regional companies such as Canon U.S.A., Canon Europe and Canon Marketing Japan, and spent ~$2.27 billion (¥339.3 billion), about 7.3% of sales, on R&D in 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of Canon Inc..

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

Canon Inc. competitive advantage: Canon's edge is vertical integration in optics and imaging. It designs its own lenses, CMOS image sensors, print engines and image-processing chips, and builds much of its own production equipment. That depth shows in its patent output (seventh in U.S. patent grants in 2025 and in the top 10 for 42 straight years, according to IFI Claims) and in a camera business that has held the No. 1 interchangeable-lens share for 23 consecutive years. In printing, a large installed base of office devices produces recurring toner and service revenue that new entrants cannot easily copy.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and Canon Inc. each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

Canon Inc. growth strategy: Phase VII sets 2030 sales targets for each unit: Printing ~$18.8 billion (¥2.8 trillion) (about 2% a year), Imaging ~$8.98 billion (¥1.34 trillion) (5%), Medical ~$5.03 billion (¥750 billion) (5%) and Industrial ~$4.02 billion (¥600 billion) (10%). Growth products named in the plan are nanoimprint lithography, photon-counting CT and industrial printing equipment. Canon merged Canon Medical Systems' operations into Canon Inc. on April 1, 2026, is taking Canon Electronics private to build a space business worth ~$134 million (¥20 billion) or more in sales by 2030, and wants emerging markets such as India, Indonesia, Africa, the Middle East and Latin America to rise from 10% to 15% of sales. In Printing it plans to cut production staff by 30% and factory space by 40% by 2028 and to outsource hardware that needs no special technology.

A closer look at the financial trajectory of AstraZeneca PLC and Canon Inc. rounds out the comparison.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.

Canon Inc.: Canon's sales fell from ~$27.3 billion (¥4,080.0 billion) in 2017, the first full year with Toshiba Medical, to ~$21.2 billion (¥3,160.2 billion) in 2020 as cameras and office printing shrank and the pandemic hit. They have grown every year since, reaching a record ~$31 billion (¥4,624.7 billion) in 2025 (+2.5%). Operating profit was ~$3.05 billion (¥455.4 billion) in 2025, a 9.8% margin, up from ~$1.87 billion (¥279.8 billion) in 2024, when a ~$1.11 billion (¥165.1 billion) goodwill impairment on the medical business cut net income to ~$1.07 billion (¥160.0 billion). Net income attributable to Canon Inc. more than doubled to ~$2.23 billion (¥332.1 billion) and EPS rose to ¥367.48. Canon paid a ¥160 dividend (42.9% payout), generated ~$1.6 billion (¥238.5 billion) of free cash flow and ended 2025 with ~$6.34 billion (¥946.2 billion) of interest-bearing debt, up from ~$4.45 billion (¥663.5 billion). By region, the Americas supplied 32% of 2025 sales, Europe 26%, Japan 21% and Asia and Oceania 21%. In July 2026, after record second-quarter sales, Canon guided to ~$32.2 billion (¥4,800.0 billion) of 2026 sales and ~$3.12 billion (¥465.0 billion) of operating profit.